A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report

Onsun, Nahide; Kaya, Gökhan; Işık, Bengisu Güçkan; Güneş, Begüm

doi:10.34172/hpp.2021.32

Cited by 58 publications

(73 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Management should be based on available guidelines as there are numerous excellent treatment options including biologics (anti-IL17, anti-IL23, anti-TNF-α). More dangerously, pustular flares of psoriasis have been described in association with COVID-19 vaccines [20]. We encountered a patient with a succulent erythematous exanthema associated with fever and malaise ten days following mRNA vaccination (case#10).…”

Section: Discussionmentioning

confidence: 99%

Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines

et al. 2021

View full text Add to dashboard Cite

(1) Background: Coronavirus disease 2019 (COVID-19) vaccines are currently employed on a population-wide scale in most countries worldwide. Data about unusual cutaneous adverse drug reactions (ADR) are scant, though. (2) Methods: We retrospectively analyzed moderate to severe vaccine-related ADR in the Department of Dermatology and Allergy of the University Hospital Bonn between May to June 2021 and analyzed related skin biopsies. (3) Results: As a specialized dermatological academic center, we encountered a total of n = 19 clinically and pathologically heterogeneous cutaneous ADR with a female predominance. Delayed cutaneous ADR occurred as late as 30 days after vaccination. The majority of ADR were mild, though a few patients required systemic treatment (antihistamines, glucocorticosteroids). (4) Conclusions: The clinico-pathological spectrum of cutaneous side effects with COVID-19 vaccines is wide; however, the benefits outweigh the risks by far. More dermatopathological studies on cutaneous ADR not limited to COVID-19 vaccines are desirable to enable a better understanding of underlying pathophysiological mechanisms.

show abstract

Section: Discussionmentioning

confidence: 99%

Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Among the very severe cutaneous ADRs, there is a condition defined by rapid onset of innumerable pustules, called acute generalized exanthematous pustulosis (AGEP), which may be seen as a mimicker of generalized psoriasis pustulosa. Interestingly, both a case of AGEP associated with a viral vector vaccine [79] and a pustular flare of psoriasis associated with an inactivated virus COVID-19 vaccine [80] have been published recently. Another case report was classified as an overlap between AGEP and drug reaction with eosinophilia and systemic symptoms (DRESS) associated with a viral vector vaccine [81].…”

Section: Neutrophilic and Pustular Drug Reactionsmentioning

confidence: 99%

“…Based on our lack of experience, we cannot draw conclusions regarding cutaneous side effects of vaccines that have been developed in Russia and China, as they are not yet approved for use in Germany. Singular case reports and case series about cutaneous side effects of these agents are available [80,91,92]. A group from the USA has published a comprehensive overview of cutaneous ADRs to various vaccines that deserves mention [93].…”

Section: Granulomatous and Fibrogenic Reactionsmentioning

confidence: 99%

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

et al. 2021

View full text Add to dashboard Cite

(1) Background: Numerous vaccines are under preclinical and clinical development for prevention of severe course and lethal outcome of coronavirus disease 2019 (COVID-19). In light of high efficacy rates and satisfactory safety profiles, some agents have already reached approval and are now distributed worldwide, with varying availability. Real-world data on cutaneous adverse drug reactions (ADRs) remain limited. (2) Methods: We performed a literature research concerning cutaneous ADRs to different COVID-19 vaccines, and incorporated our own experiences. (3) Results: Injection site reactions are the most frequent side effects arising from all vaccine types. Moreover, delayed cutaneous ADRs may occur after several days, either as a primary manifestation or as a flare of a pre-existing inflammatory dermatosis. Cutaneous ADRs may be divided according to their cytokine profile, based on the preponderance of specific T-cell subsets (i.e., Th1, Th2, Th17/22, Tregs). Specific cutaneous ADRs mimic immunogenic reactions to the natural infection with SARS-CoV-2, which is associated with an abundance of type I interferons. (4) Conclusions: Further studies are required in order to determine the best suitable vaccine type for individual groups of patients, including patients suffering from chronic inflammatory dermatoses.

show abstract

“…Wide range of cutaneous side effects are being reported with different types of SARS-CoV-2 vaccines including early-onset or delayed-type local injection reactions, maculopapular rash, erythema multiforme, pernio and urticaria. [48] Exacerbation of chronic inflammatory skin disorders such as psoriasis has also been recently described [49][50][51][52][53].…”

Section: Covid-19 Vaccines and Exacerbation Of Psoriasismentioning

confidence: 99%

Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy

Diotallevi

Campanati

Radi

et al. 2021

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

More than 12 months have passed since the World Health Organization (WHO) declared Coronavirus Disease 19 (COVID-19), caused by the SARS-CoV2 virus, to be a pandemic on 11 March 2020. The entire world scientific community agrees that at this time vaccine is the most promising weapon to combat the infection and the severity of the disease. According to the document “Draft landscape of COVID-19 candidate vaccines” by WHO, 272 vaccines against SARS-CoV-2 virus are in development, although only four of these, produced by Pfizer-BioNTech (Pfizer, Inc. and BioNTech), Moderna, AstraZeneca, and Janssen companies, respectively, have been approved by European Medicines Agency and Italian Medicines Agency and subsequently distributed nationwide for use. These vaccines are the result of highly innovative procedures and are quite different from each other in terms of composition. Even clinicians in various medical fields may be unfamiliar with the effects of these vaccines. There is the strong emerging need for dermatologists to understand the crucial role of vaccines, with a focus on the need to vaccinate patients suffering from immune-mediated skin diseases, such as psoriasis, while taking the ongoing treatment into consideration regarding the timing of vaccination. Similarly, psoriasis patients aware of having an immune-mediated and inflammatory disease are increasingly asking the dermatologist information about the efficacy and safety of vaccines against SARS-CoV-2 virus. In this narrative review of the literature and critical analysis of the recommendations of the Italian Ministry of Health, we analyze the implications of the vaccination campaign on dermatological patients with psoriasis undergoing immunosuppressive treatment.

show abstract

A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report

Cited by 58 publications

References 8 publications

Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines

Single-Center Clinico-Pathological Case Study of 19 Patients with Cutaneous Adverse Reactions Following COVID-19 Vaccines

Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective

Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy

Contact Info

Product

Resources

About